Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology

11Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG), a glucose analog, is widely used throughout the world as an indispensable imaging modality for the management of cancer treatment. This article reviews the pioneering achievements of PET in oncology with a focus on the development of PET that occurred from 1980 through the early-1990s. 18F-FDG was first applied for imaging of animal tumors in 1980 and for brain tumor imaging clinically in 1982. 18F-FDG enabled to visualize liver metastasis as clear positive image that could not be obtained by conventional nuclear imaging. Subsequently, 18F-FDG was used for imaging various cancers, such as lung, pancreas, colorectal and hepatoma. 11C-L-methionine (11C-MET) that reflects amino acid transport of cancers has an advantage that its uptake is lower in the brain and inflammatory tissue compared to 18F-FDG, and was first applied for imaging lung cancer and brain tumor. 18F-FDG and 11C-MET were proved to be sensitive tracers that can be used to objectively evaluate the effectiveness of cancer treatment. The diagnostic accuracy of PET, which is critical in clinical practice, was evaluated for the differential diagnosis of malignant and benign lung nodules using 18F-FDG or 11C-MET. In addition to 18F-FDG and 11C-MET, many radiopharmaceuticals were developed, such as 18F-labled thymidine analogs for evaluating proliferative activity, 18F-fluoromisonidazole for imaging of hypoxia, and 18F-fluorodeoxygalactose for evaluating liver-specific galactose metabolism and for imaging of hepatoma that retains galactose metabolic activity. These early efforts and achievements have greatly contributed to the development and clinical application of 18F-FDG PET in oncology. © 2013 Tohoku University Medical Press.

References Powered by Scopus

THE [<sup>14</sup>C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT

5011Citations
N/AReaders
Get full text

Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method

2052Citations
N/AReaders
Get full text

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

1513Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Hyperpolarized carbon-13 MRI and MRS studies

11Citations
N/AReaders
Get full text

Anticancer therapeutics: From drug discovery to clinical applications

8Citations
N/AReaders
Get full text

Noninvasive evaluation of <sup>18</sup>F-FDG/<sup>18</sup>F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Fukuda, H., Kubota, K., & Matsuzawa, T. (2013). Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology. Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.230.155

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

80%

Professor / Associate Prof. 2

10%

Researcher 2

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

68%

Chemistry 2

11%

Nursing and Health Professions 2

11%

Biochemistry, Genetics and Molecular Bi... 2

11%

Save time finding and organizing research with Mendeley

Sign up for free